Alere (ALR) Reports Q3 Revenue of $582M, Below Consensus

November 4, 2016 9:57 AM EDT

Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.

Alere Inc. (NYSE: ALR), a global leader in rapid diagnostic tests, today announced that it has filed its Form 10-Q and reported financial results for the third quarter ended September 30, 2016.

Revenue for the third quarter of 2016 was $582 million, a 4% decrease compared to $604 million in the prior year period. Infectious disease revenue grew 11% or $19 million year-over-year with strength in Africa and Latin America, particularly in malaria and HIV product sales. This strong growth was offset by revenue declines of $15 million due to the divestiture of BBI in November 2015, $12 million in mail order diabetes and $7 million in Toxicology. Foreign currency had a negative impact of $4 million and organic growth was -0.7% during the third quarter of 2016.

Net income (loss) from continuing operations during the third quarter of 2016 was $22 million, or $0.19 per basic and diluted share, compared to $(2) million, or $(0.10) per basic and diluted share in the prior year period. On a non-GAAP basis, the Company reported non-GAAP adjusted EBITDA of $64 million in the third quarter of 2016, compared to $135 million in the prior year period. The year-over-year decrease was primarily driven by $41 million in merger and legal-related expenses, $12 million of investments in infrastructure and performance improvement initiatives and $5 million in acquisition costs.

(Street sees Q3 EPS of 54c on revenue of $605.5 million.)

Revenue (in millions)

Third Quarter 2016

Third

Quarter 2015

% Change

Cardiometabolic Disease

$

189

$

209

(10%)

Infectious Disease

183

165

11%

Toxicology

156

163

(4%)

Other

33

45

(28%)

Consumer Diagnostics

19

19

-

License and Royalty

2

3

(25%)

Total

$

582

$

604

(4%)

Certain amounts presented may not recalculate directly, due to rounding.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Corporate News, Earnings, Hot Corp. News, Trading Halts

Related Entities

Dividend, Earnings, Definitive Agreement

Add Your Comment